Table 3.

mAbs authorized for the treatment of MS in the US (up until September 2022): administration routes, dosing regimens and product presentations (adult indications)

mAb	Administration route and dosing regimena		IV product presentationsa	SC product presentationsa
	IV	SC
Natalizumab	300 mg q4w	-b	300 mg/15 mL in single-dose vial	-b
Alemtuzumab	Initial treatment (2 courses): First course of 12 mg/day on 5 consecutive days; second course of 12 mg/day on 3 consecutive days 12 months after first treatment course Subsequent treatment courses: 12 mg/day on 3 consecutive days as needed, at least 12 months after the previous course	-	12 mg/1.2 mL in single-dose vial	-
Ocrelizumab	Start dose: 2*300 mg separated by two weeks Subsequent doses: 600 mg q6m	-	300 mg/10 mL in single-dose vial
Ofatumumab	-	Initial dosing: 20 mg administered at weeks 0, 1, and 2 Subsequent dosing: 20 mg q1m starting at week 4	-	20 mg/0.4 mL solution in single-dose prefilled pen or single-dose prefilled syringe

IV intravenous, mg milligram, mL milliliter, qXd every X day, qXm every X month, qXw every X week, SC subcutaneous

^aThis table lists FDA-approved products; deviations with EMA-approved product presentations are indicated as a footnote

^bA SC formulation for natalizumab in MS is approved in the EU